Looking to the future: A new decade of pulmonary arterial hypertension therapy

European Respiratory Review

Volumn 20, Issue 122, 2011, Pages 262-269

  McLaughlin, V V ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Endothelin receptor antagonist; Nitric oxide; Prostacyclin; Pulmonary arterial hypertension; Serotonin receptor antagonist; Tyrosine kinase inhibitor

Indexed keywords

AMBRISENTAN; BERAPROST; BOSENTAN; DICHLOROACETIC ACID; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; IMATINIB; MACITENTAN; NILOTINIB; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTANOID; PROTEIN TYROSINE KINASE INHIBITOR; RIOCIGUAT; SAPROPTERIN; SELEXIPAG; SEROTONIN; SEROTONIN ANTAGONIST; SILDENAFIL; SORAFENIB; TERGURIDE; UNIPROST;

CONTINUOUS INFUSION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; HEART ARREST; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; INJECTION SITE REACTION; KIDNEY FAILURE; LIVER DYSFUNCTION; LIVER TOXICITY; NONHUMAN; PATHOGENESIS; PRESYNCOPE; PULMONARY HYPERTENSION; REVIEW; SURVIVAL; SYNCOPE;

ANTIHYPERTENSIVE AGENTS; BIOMEDICAL RESEARCH; ENZYME INHIBITORS; HUMANS; HYPERTENSION, PULMONARY; PROGNOSIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 82555195583     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00006411     Document Type: Review

References (100)

1. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163.
2. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.
3. Humbert M, Sitbon O, Simonneau, G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
4. Rubin LJ. Therapy of pulmonary hypertension: the evolution from vasodilators to antiproliferative agents. Am J Respir Crit Care Med 2002; 166: 1308-1309.
5. Channick R, Badesch DB, Tapson VF, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. J Heart Lung Transplant 2001; 20: 262-263.
6. Sitbon O, Badesch DB, Channick RN, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003; 124: 247-254.
7. Sitbon O, McLaughlin VV, Badesch DB, et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 2005; 60: 1025-1030.
8. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
9. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with firstline bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005; 25: 244-249.
10. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117: 3010-3019.
11. McGoon MD, Frost AE, Oudiz RJ, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest 2009; 135: 122-129.
12. Oudiz RJ, Galiè N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: 1971-1981.
13. Shi-Wen X, Denton CP, Dashwood MR, et al. Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol 2001; 116: 417-425.
14. Yang Z, Krasnici N, Lüscher TF. Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade. Circulation 1999; 100: 5-8.
15. Hocher B, Schwarz A, Fagan KA, et al. Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am J Respir Cell Mol Biol 2000; 23: 19-26.
16. Wagner OF, Christ G, Wojta J, et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992; 267: 16066-16068.
17. Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008; 327: 736-745.
18. Raja SG. Macitentan: a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis. Curr Opin Investig Drugs 2010; 11: 1066-1073.
19. ClinicalTrials.gov. Study of ACT-064992 on morbidity and mortality in patients with symptomatic pulmonary arterial hypertension. NCT00660179. http://clinicaltrials.gov/ct2/show/NCT00660179 Date last updated: May 20, 2011. Date last accessed: August 9, 2011.
20. McLaughlin VV, Badesch DB, Delcroix M, et al. End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S97-S107.
21. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990; 112: 485-491.
22. Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994; 121: 409-415.
23. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477-1482.
24. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800-804.
25. Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006; 28: 1195-1203.
26. Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-329.
27. Olschewski H, Hoeper MM, Behr J, et al. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respir Med 2010; 104: 731-740.
28. Hoeper MM, Gall H, Seyfarth HJ, et al. Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. Eur Respir J 2009; 34: 132-137.
29. Channick RN, Olschewski H, Seeger W, et al. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol 2006; 48: 1433-1437.
30. Voswinckel R, Enke B, Reichenberger F, et al. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol 2006; 48: 1672-1681.
31. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010; 55: 1915-1922.
32. Galiè N, Humbert M, Vachiéry JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39: 1496-1502.
33. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 2119-2125.
34. Mubarak KK. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir Med 2010; 104: 9-21.
35. Kuwano K, Hashino A, Asaki T, et al. 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther 2007; 322: 1181-1188.
36. Kuwano K, Hashino A, Noda K, et al. A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-[4-[(5,6-diphenyl pyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, [4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]acetic acid (MRE-269), on rat pulmonary artery. J Pharmacol Exp Ther 2008; 326: 691-699.
37. Simonneau G, Lang I, Torbicki A, et al. Efficacy, safety and tolerability of ACT-293987, a novel oral, non-prostanoid, prostaglandin I2 (IP) receptor agonist: results from a phase IIa study in pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med 2010; 181: A2515.
38. ClinicalTrials.gov. ACT-293987 in pulmonary arterial hypertension. NCT01106014. http://clinicaltrials.gov/ct2/show/NCT01106014 Date last updated: July 27, 2011. Date last accessed: August 9, 2011.
39. Tapson VF, Torres F, Kermeen F, et al. Results of the FREEDOM-C Study: a pivotal study of oral treprostinil used adjunctively with an ERA and/or PDE5-inhibitor for the treatment of PAH. Am J Respir Crit Care Med 2009; 179: A1040.
40. United Therapeutics. FREEDOM-M Trial of oral treprostinil in pulmonary arterial hypertension meets primary endpoint. http://ir.unither.com/releasedetail.cfm?ReleaseID5582786 Date last updated: June 6, 2011. Date last accessed: August 9, 2011.
41. ClinicalTrials.gov. An open-label extension trial of UT-15C SR in subjects with pulmonary arterial hypertension (FREEDOM-EXT). NCT 01027949. http://clinicaltrials.gov/ct2/show/NCT01027949 Date last updated October 8, 2010. Date last accessed: August 9, 2011.
42. ClinicalTrials.gov. A 16-week, international, multicenter, doubleblind, randomized, placebo-controlled study of the efficacy and safety of oral UT-15C sustained release tablets in subjects with pulmonary arterial hypertension (FREEDOM-C2). NCT00887978. http://clinicaltrials.gov/ct2/show/NCT00887978 Date last updated: May 5, 2011. Date last accessed: August 9, 2011.
43. Crosswhite P, Sun Z. Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension. J Hypertens 2010; 28: 201-212.
44. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333: 214-221.
45. Sitbon O, Brenot F, Denjean A, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 1995; 151: 384-389.
46. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157.
47. Rubin LJ, Badesch DB, Fleming TR, et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: SUPER-2. Chest 2011; [Epub ahead of print DOI: 10.1378/ chest.10-0969].
48. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894-2903.
49. Ghofrani HA, Voswinckel R, Gall H, et al. Riociguat for pulmonary hypertension. Future Cardiol 2010; 6: 155-166.
50. Evgenov OV, Kohane DS, Bloch KD, et al. Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation. Am J Respir Crit Care Med 2007; 176: 1138-1145.
51. Ghofrani HA, Hoeper MM, Halank M, et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J 2010; 36: 792-799.
52. Mittendorf J, Weigand S, Alonso-Alija C, et al. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem 2009; 4: 853-865.
53. Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005; 115: 2811-2821.
54. Schermuly RT, Stasch JP, Pullamsetti SS, et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 2008; 32: 881-891.
55. Grimminger F, Weimann G, Frey R, et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 2009; 33: 785-792.
56. ClinicalTrials.gov. A study to evaluate efficacy and safety of oral BAY63-2521 in patients with pulmonary arterial hypertension (PAH) (PATENT-1). NCT00810693. http://clinicaltrials.gov/ct2/show/NCT00810693 Date last updated: August 4, 2011. Date last accessed: August 9, 2011.
57. ClinicalTrials.gov. A study to evaluate efficacy and safety of oral BAY63-2521 in patients with CTEPH (CHEST-1). NCT00855465. http://clinicaltrials.gov/ct2/show/NCT00855465 Date last updated: July 27, 2011. Date last accessed: August 9, 2011.
58. Paulin R, Courboulin A, Barrier M, et al. From oncoproteins/tumor suppressors to microRNAs: the newest therapeutic targets for pulmonary arterial hypertension. J Mol Med (Berl) 2011; [Epub ahead of print DOI: 10.1007/s00109-011-0788-5].
59. Sakao S, Tatsumi K. Vascular remodeling in pulmonary arterial hypertension: multiple cancer-like pathways and possible treatment modalities. Int J Cardiol 2011; 147: 4-12.
60. Klein M, Schermuly RT, Ellinghaus P, et al. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation 2008; 118: 2081-2090.
61. Steeghs N, Nortier JW, Gelderblom H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann Surg Oncol 2007; 14: 942-953.
62. Grimminger F, Schermuly RT. PDGF receptor and its antagonists: role in treatment of PAH. Adv Exp Med Biol 2010; 661: 435-446.
63. Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature Med 2006; 12: 908-916.
64. Barst RJ. PDGF signaling in pulmonary arterial hypertension. J Clin Invest 2005; 115: 2691-264.
65. Nakamura K, Akagi S, Ogawa A, et al. Pro-apoptotic effects of imatinib on PDGF-stimulated pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. Int J Cardiol 2011; [Epub ahead of print DOI: 10.1016/ j.ijcard.2011.02.024].
66. Hatano M, Yao A, Shiga T, et al. Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension. Int Heart J 2010; 51: 272-276.
67. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005; 353: 1412-1413.
68. Ghofrani HA, Morrell NW, Hoeper MM, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010; 182: 1171-1177.
69. Souza R, Sitbon O, Parent F, et al. Long term imatinib treatment in pulmonary arterial hypertension. Thorax 2006; 61: 736.
70. ten Freyhaus H, Dumitrescu D, Bovenschulte H, et al. Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension. Clin Res Cardiol 2009; 98: 265-267.
71. García Hernández FJ, Castillo Palma MJ, González León R, et al. Experience with imatinib to treat pulmonary arterial hypertension. Arch Bronconeumol 2008; 44: 689-691.
72. ClinicalTrials.gov. Imatinib in pulmonary arterial hypertension (IMPRES). NCT00902174. http://clinicaltrials.gov/ct2/show/NCT00902174 Date last updated: December 1, 2010. Date last accessed: August 9, 2011.
73. ClinicalTrials.gov. Extension to QTI571A2301 to evaluate the long-term safety, tolerability and efficacy of imatinib in severe pulmonary arterial hypertension (IMPRES Extn). NCT01117987. http://clinicaltrials.gov/ct2/show/NCT01117987 Date last updated: October 22, 2011. Date last accessed: August 9, 2011.
74. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinibresistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542-2551.
75. Duggan N, Bonneau O, Hussey M, et al. Comparison of effects of imatinib and nilotinib in a rodent model of pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 181: A6304.
76. ClinicalTrials.gov. Efficacy, safety, tolerability and pharmacokinetics (PK) of nilotinib (AMN107) in pulmonary arterial hypertension (PAH). NCT01179737. http://clinicaltrials.gov/ct2/show/NCT01179737 Date last updated: August 10, 2010. Date last accessed: August 9, 2011.
77. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 335: 609-616.
78. Dempsie Y, MacLean MR. Pulmonary hypertension: therapeutic targets within the serotonin system. Br J Pharmacol 2008; 155: 455-462.
79. Hervé P, Launay J-M, Scrobohaci M-L, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99: 249-254.
80. Eddahibi S, Humbert M, Fadel E, et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001; 108: 1141-1150.
81. Eddahibi S, Raffestin B, Pham I, et al. Treatment with 5-HT potentiates development of pulmonary hypertension in chronically hypoxic rats. Am J Physiol Heart Circ Physiol 1997; 41: H1173-H1181.
82. Hironaka E, Hongo M, Sakai A, et al. Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Cardiovasc Res 2003; 60: 692-699.
83. Guignabert C, Raffestin B, Benferhat R, et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 2005; 111: 2812-2819.
84. Kawut SM, Horn EM, Berekashvili KK, et al. Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. Pulmon Pharmacol Therapeut 2006; 19: 370-374.
85. Shah SJ, Gomberg-Maitland M, Thenappan T, et al. Selective serotonin reuptake inhibitors and the incidence and outcome of pulmonary hypertension. Chest 2009; 136: 694-700.
86. Keegan A, Morecroft I, Smillie D, et al. Contribution of the 5-HT(1B) receptor to hypoxia-induced pulmonary hypertension: converging evidence using 5-HT(1B)-receptor knockout mice and the 5-HT(1B/1D)-receptor antagonist GR127935. Circ Res 2001; 89: 1231-1239.
87. Launay JM, Hervé P, Peoc'h K, et al. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 2002; 8: 1129-1135.
88. Dumitrascu R, Kulcke C, Königshoff M, et al. Terguride ameliorates monocrotaline induced pulmonary hypertension in rats. Eur Respir J 2011; 37: 1104-1118.
89. Ergonex. Ergonex Pharma initiates Phase II clinical trial of terguride in pulmonary arterial hypertension. www.ergonex.com/attachments/news/26/Media_Release_final_V2.pdf Date last updated: January 29, 2008. Date last accessed: August 9, 2011.
90. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.
91. Moreno-Vinasco L, Garcia JG. Receptor tyrosine kinase inhibitors in rodent pulmonary hypertension. Adv Exp Med Biol 2010; 661: 419-434.
92. Gomberg-Maitland M, Maitland ML, Barst RJ, et al. A dosing/ cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2010; 87: 303-310.
93. ClinicalTrials.gov. Sorafenib study: dosing in patients with pulmonary arterial hypertension (PAH). NCT00452218. http://clinicaltrials.gov/ct2/show/NCT00452218 Date last updated: August 2, 2011. Date last accessed: August 9, 2011.
94. Pritchard KA Jr, Shi Y, Konduri GG. Tetrahydrobiopterin in pulmonary hypertension: pulmonary hypertension in guanosine triphosphate-cyclohydrolase-deficient mice. Circulation 2005; 111: 2022-2024.
95. Robbins IM, Hemnes AR, Gibbs JS, et al. Safety of sapropterin dihydrochloride (6r-bh4) in patients with pulmonary hypertension. Exp Lung Res 2011; 37: 26-34.
96. ClinicalTrials.gov. 6R-BH4 pulmonary arterial hypertension study. NCT00435331. http://clinicaltrials.gov/ct2/show/NCT00435331 Date last updated: April 17, 2011. Date last accessed: August 9, 2011.
97. McMurtry MS, Bonnet S, Wu X, et al. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res 2004; 95: 830-840.
98. Michelakis ED, McMurtry MS, Wu XC, et al. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation 2002; 105: 244-250.
99. Guignabert C, Tu L, Izikki M, et al. Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22alpha-targeted overexpression of the serotonin transporter. FASEB J 2009; 23: 4135-4147.
100. ClinicalTrials.gov. Dichloroacetate (DCA) for the treatment of pulmonary arterial hypertension. NCT01083524. http://clinicaltrials.gov/ct2/show/NCT01083524 Date last updated: March 9, 2010. Date last accessed: August 9, 2011.